Abstract

As more children are appropriately being diagnosed, the burden of sickle cell disease is increasing greatly in Africa and in high-resource countries such as the United States and Europe. Early management is mandatory, but newborn screening is not implemented everywhere. Point-of-care testing devices are increasingly being used in low-resource countries, showing good sensitivity and specificity. Because the diagnosis is often traumatic for the families, the announcement should be made by an experienced person. The development of care networks is urgently required to facilitate daily life by defining the respective functions of nearby and highly specialized health care professionals, who should work in close collaboration. Comprehensive programs targeting the prevention of pneumococcal infections, malaria in infested zones, and stroke may substantially improve patient care. Hydroxyurea is increasingly being used, but whether it should be systematically prescribed in all children is debated, and its access is still limited in many African countries. Yearly checkups should be organized early in life in order to screen and then treat any organ impairment. Enhancing parents’ and patients’ knowledge and skills is mandatory.

References

References
1.
Piel
FB
,
Hay
SI
,
Gupta
S
,
Weatherall
DJ
,
Williams
TN
.
Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions
.
PLoS Med
.
2013
;
10
(
7
):
e1001484
.
2.
Quinn
CT
,
Rogers
ZR
,
McCavit
TL
,
Buchanan
GR
.
Improved survival of children and adolescents with sickle cell disease
.
Blood
.
2010
;
115
(
17
):
3447
-
3452
.
3.
Couque
N
,
Girard
D
,
Ducrocq
R
, et al
.
Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines
.
Br J Haematol
.
2016
;
173
(
6
):
927
-
937
.
4.
Telfer
P
,
Coen
P
,
Chakravorty
S
, et al
.
Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London
.
Haematologica
.
2007
;
92
(
7
):
905
-
912
.
5.
Makani
J
,
Cox
SE
,
Soka
D
, et al
.
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania
.
PLoS One
.
2011
;
6
(
2
):
e14699
.
6.
Rahimy
MC
,
Gangbo
A
,
Ahouignan
G
, et al
.
Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting
.
Blood
.
2003
;
102
(
3
):
834
-
838
.
7.
Lobitz
S
,
Telfer
P
,
Cela
E
, et al
;
with the endorsement of EuroBloodNet, the European Reference Network in Rare Haematological Diseases
.
Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference
.
Br J Haematol
.
2018
;
183
(
4
):
648
-
660
.
8.
Streetly
A
,
Sisodia
R
,
Dick
M
,
Latinovic
R
,
Hounsell
K
,
Dormandy
E
.
Evaluation of newborn sickle cell screening programme in England: 2010-2016
.
Arch Dis Child
.
2018
;
103
(
7
):
648
-
653
.
9.
Ware
RE
,
de Montalembert
M
,
Tshilolo
L
,
Abboud
MR
.
Sickle cell disease
.
Lancet
.
2017
;
390
(
10091
):
311
-
323
.
10.
Kanter
J
,
Telen
MJ
,
Hoppe
C
,
Roberts
CL
,
Kim
JS
,
Yang
X
.
Validation of a novel point of care testing device for sickle cell disease
.
BMC Med
.
2015
;
13
(
1
):
225
.
11.
Smart
LR
,
Ambrose
EE
,
Raphael
KC
, et al
.
Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study
.
Ann Hematol
.
2018
;
97
(
2
):
239
-
246
.
12.
Nnodu
O
,
Isa
H
,
Nwegbu
M
, et al
.
HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: promises and challenges
.
Blood Cells Mol Dis
.
2019
;
78
:
22
-
28
.
13.
Steele
C
,
Sinski
A
,
Asibey
J
, et al
.
Point-of-care screening for sickle cell disease in low-resource settings: a multi-center evaluation of HemoTypeSC, a novel rapid test
.
Am J Hematol
.
2019
;
94
(
1
):
39
-
45
.
14.
Thornburg
CD
,
Ware
RE
.
Children with sickle cell disease migrating to the United States from sub-Saharan Africa
.
Pediatr Blood Cancer
.
2018
;
65
(
6
):
e27000
.
15.
Hirst
C
,
Owusu-Ofori
S
.
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
.
Cochrane Database Syst Rev
.
2012
;(
9
):
CD003427
.
16.
Martin
OO
,
Moquist
KL
,
Hennessy
JM
,
Nelson
SC
.
Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era
.
Pediatr Blood Cancer
.
2018
;
65
(
1
):
e26713
.
17.
McCavit
TL
,
Quinn
CT
,
Techasaensiri
C
,
Rogers
ZR
.
Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure
.
J Pediatr
.
2011
;
158
(
3
):
505
-
507
.
18.
Oligbu
G
,
Collins
S
,
Sheppard
C
, et al
.
Risk of invasive pneumococcal disease in children with sickle cell disease in England: a national observational cohort study, 2010-2015
.
Arch Dis Child
.
2018
;
103
(
7
):
643
-
647
.
19.
Oligbu
G
,
Fallaha
M
,
Pay
L
,
Ladhani
S
.
Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature
.
Br J Haematol
.
2019
;
185
(
4
):
743
-
751
.
20.
Tluway
F
,
Makani
J
.
Sickle cell disease in Africa: an overview of the integrated approach to health, research, education and advocacy in Tanzania, 2004-2016
.
Br J Haematol
.
2017
;
177
(
6
):
919
-
929
.
21.
Adams
R
,
McKie
V
,
Nichols
F
, et al
.
The use of transcranial ultrasonography to predict stroke in sickle cell disease
.
N Engl J Med
.
1992
;
326
(
9
):
605
-
610
.
22.
Adams
RJ
,
McKie
VC
,
Hsu
L
, et al
.
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography
.
N Engl J Med
.
1998
;
339
(
1
):
5
-
11
.
23.
Abdullahi
SU
,
DeBaun
MR
,
Jordan
LC
,
Rodeghier
M
,
Galadanci
NA
.
Stroke recurrence in Nigerian children with sickle cell disease: evidence for a secondary prevention trial
.
Pediatr Neurol
.
2019
;
95
:
73
-
78
.
24.
Ferster
A
,
Vermylen
C
,
Cornu
G
, et al
.
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial
.
Blood
.
1996
;
88
(
6
):
1960
-
1964
.
25.
Wang
WC
,
Ware
RE
,
Miller
ST
, et al
;
BABY HUG investigators
.
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
.
Lancet
.
2011
;
377
(
9778
):
1663
-
1672
.
26.
Ware
RE
,
Davis
BR
,
Schultz
WH
, et al
.
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
.
Lancet
.
2016
;
387
(
10019
):
661
-
670
.
27.
Hankins
JS
,
Aygun
B
,
Nottage
K
, et al
.
From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia
.
Medicine (Baltimore)
.
2014
;
93
(
28
):
e215
.
28.
Zimmerman
SA
,
Schultz
WH
,
Davis
JS
, et al
.
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
.
Blood
.
2004
;
103
(
6
):
2039
-
2045
.
29.
de Montalembert
M
,
Brousse
V
,
Elie
C
,
Bernaudin
F
,
Shi
J
,
Landais
P
;
French Study Group on Sickle Cell Disease
.
Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes
.
Haematologica
.
2006
;
91
(
1
):
125
-
128
.
30.
Gulbis
B
,
Haberman
D
,
Dufour
D
, et al
.
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience
.
Blood
.
2005
;
105
(
7
):
2685
-
2690
.
31.
Colombatti
R
,
Palazzi
G
,
Masera
N
, et al
;
Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators
.
Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: results of a national multicenter survey
.
Pediatr Blood Cancer
.
2018
;
65
(
2
):
e26774
.
32.
PQ
,
Gulbis
B
,
Dedeken
L
, et al
.
Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment
.
Pediatr Blood Cancer
.
2015
;
62
(
11
):
1956
-
1961
.
33.
Yawn
BP
,
Buchanan
GR
,
Afenyi-Annan
AN
, et al
.
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members
.
JAMA
.
2014
;
312
(
10
):
1033
-
1048
.
34.
Stukenborg
JB
,
Alves-Lopes
JP
,
Kurek
M
, et al
.
Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy
.
Hum Reprod
.
2018
;
33
(
9
):
1677
-
1683
.
35.
Opoka
RO
,
Ndugwa
CM
,
Latham
TS
, et al
.
Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia
.
Blood
.
2017
;
130
(
24
):
2585
-
2593
.
36.
Tshilolo
L
,
Tomlinson
G
,
Williams
TN
, et al
;
REACH Investigators
.
Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa
.
N Engl J Med
.
2019
;
380
(
2
):
121
-
131
.
37.
Gluckman
E
,
Cappelli
B
,
Bernaudin
F
, et al
;
Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research
.
Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation
.
Blood
.
2017
;
129
(
11
):
1548
-
1556
.
38.
de Montalembert
M
,
Ferster
A
,
Colombatti
R
,
Rees
DC
,
Gulbis
B
;
European Network for Rare and Congenital Anaemias
.
ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children
.
Am J Hematol
.
2011
;
86
(
1
):
72
-
75
.
39.
DeBaun
MR
,
Armstrong
FD
,
McKinstry
RC
,
Ware
RE
,
Vichinsky
E
,
Kirkham
FJ
.
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia
.
Blood
.
2012
;
119
(
20
):
4587
-
4596
.
40.
Hofmann
M
,
de Montalembert
M
,
Beauquier-Maccotta
B
,
de Villartay
P
,
Golse
B
.
Posttraumatic stress disorder in children affected by sickle-cell disease and their parents
.
Am J Hematol
.
2007
;
82
(
2
):
171
-
172
.
You do not currently have access to this content.